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Abstract  Autoimmune  pancreatitis  is  emerging  as  a  well-deﬁned  clinical  entity,  yet  its  diag-
nosis and  therapeutic  approach  still  constitute  a  clinical  challenge.  Its  association  to  other
autoimmune  diseases,  namely  ulcerative  colitis,  is  known  although  the  exact  relationship
between  the  two  entities  is  not  completely  clariﬁed.
We present  the  case  of  a  patient  who  developed  obstructive  jaundice  with  later  onset  of
blood-stained  diarrhea,  leading  to  a  ﬁnal  diagnosis  of  autoimmune  pancreatitis  and  ulcerative
colitis.
We make  a  brief  revision  of  autoimmune  pancreatitis,  its  relationship  with  ulcerative  colitis
and therapeutic  approaches  of  the  same,  namely  the  eventual  necessity  of  immunosuppressive
therapy.
© 2011  Sociedade  Portuguesa  de  Gastrenterologia  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Pancreatite  auto-imune  e  colite  ulcerosa:  um  desaﬁo  clínico  de  uma  associac¸ão  real
Resumo  A  pancreatite  auto-imune  é  compreendida  cada  vez  mais  como  uma  entidade  clínica
bem deﬁnida,  contudo  o  seu  diagnóstico  e  abordagem  terapêutica  constitui  ainda  um  desaﬁo
clínico. A  sua  associac¸ão  com  outras  doenc¸as  auto-imunes,  nomeadamente  com  a  colite  ulcerosaDoenc¸a  inﬂamatória
intestinal;
Imunosupressão
é conhecida  porém  a  verdadeira  relac¸ão  entre  as  duas  entidades  não  está  totalmente  esclare-
cida.
Apresentamos  o  caso  clínico  de  um  doente  que  iniciou  quadro  de  icterícia  obstrutiva
chegando-se  ao  diagnóstico  ﬁnal  de  pancreatite  auto-imune.  Durante  a  investigac¸ão  clínica
o doente  apresenta  quadro  de  diarreia  sanguinolenta  diagnosticando-se  colite  ulcerosa  extensa
associada.
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Fazemos  uma  breve  revisão  da  pancreatite  auto-imune,  da  sua  relac¸ão  com  a  colite  ulcerosa
e abordagem  terapêutica  das  mesmas  nomeadamente  perante  a  eventual  necessidade  de  ter-
apêutica imunosupressora.
©  2011  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
Figure  1  Endoscopic  retrograde  cholangiopancreatography.
(A) Tight  stenosis  of  the  intrapancreatic  portion  of  the  common
biliary  duct  with  upstream  dilatation.  (B)  Placement  of  plastic
biliary  stent  (10  Fr)  through  the  stenosis.Introduction
For  decades,  different  cases  of  chronic  pancreatitis  associ-
ated  with  an  important  immunological  component  have  been
recognized.  In  1961,  Sarles  et  al.  used  the  term  ‘‘primary
inﬂammatory  pancreatitis’’  to  describe  a  group  of  patients
with  pancreatitis,  until  then  of  unknown  aetiology,  who  pre-
sented  little  or  no  abdominal  pain,  cholestasis,  increased
serum  immunoglobulins  and  severe  pancreatic  inﬂamma-
tory  inﬁltrate  with  ﬁbrosis.1 Since  then  many  terms  were
employed  to  describe  cases  of  pancreatitis  with  similar  char-
acteristics  until  1995  when,  for  the  ﬁrst  time,  the  term
autoimmune  pancreatitis  (AIP)  was  applied.2 From  this  date,
many  advances  in  the  understanding  of  this  entity  have  been
recorded.
At  the  same  time,  an  increased  incidence  of  pancreatic
diseases  in  patients  with  inﬂammatory  bowel  disease  (IBD)
has  been  reported,  namely  with  ulcerative  colitis  (UC).  This
may  be  drug-related  or  due  to  the  increased  incidence  of
cholelithiasis  among  IBD  patients.3 However  rarer  forms  of
chronic  pancreatitis  are  described,  and  its  association  with
AIP  is  underlined  by  different  case  reports,  although  the  true
incidence  is  still  unknown.3--5
Clinical case
We  present  the  case  of  a  34-year-old  white  man  with  no  past
medical  history  who  developed  malaise,  fatigue,  persistent
epigastric  discomfort  and  one  month  later  jaundice.  There
was  no  history  of  alcohol  intake,  drug  abuse  or  medication.
The  physical  exam  was  unremarkable  except  for  jaundice
and  epigastric  pain.  Laboratory  evaluation  was  remarkable
for  abnormal  liver  function  tests  with  cholestasis  and  slight
hepatic  cytolysis  (alkaline  phosphatase,  340  UI/L;  gamma-
glutamyl  transferase,  191  UI/L;  total  bilirubin,  5.57  mg/dl;
aspartate  aminotransferase,  86  UI/L;  alanine  aminotrans-
ferase,  102  UI/L).  Abdominal  ultrasound  was  consistent
with  extra-hepatic  cholestasis  and  an  abdominal  computed
tomography  (CT)  documented  common  bile  duct  (CBD)  nar-
rowing  at  the  pancreatic  level,  which  was  described  as
normal.  The  endoscopic  retrograde  cholangiopancreatog-
raphy  (ERCP)  conﬁrmed  the  intra-pancreatic  regular  CBD
stenosis  without  further  changes  of  the  extra-pancreatic  bile
structures  (Fig.  1A).  Biliary  citology  was  negative  for  malig-
nancy.  Pancreatic  duct  canulation  was  unsuccessful  and  a
10  Fr  biliary  stent  was  placed  (Fig.  1B).
For  further  evaluation  a  magnetic  resonance  imaging-
cholangiopancreatography  (MRI-CP)  was  ordered,  which
revealed  discrete  pancreatic  head  heterogeneity,  with  no
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Figure  2  Endoscopic  ultrasonography.  (A)  Pancreatic  head
with irregular  contours  and  heterogeneous  echo  structure  with  a
slight increase  in  its  size  (HEAD  -- pancreatic  head;  CBD  --  com-
mon biliary  duct;  N  -- reactive  lymphoid  nodule;  PV  -- portal
vein; SV  -- splenic  vein).  (B)  Pancreatic  isthmus  characteristics
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Figure  3  Histopathological  images  of  pancreatic  puncture.
(A) and  (B)  Total  loss  of  lobular  structure  with  extensive  pancre-
atic ﬁbrosis  and  periductal  lymphocytic  inﬁltration  associated
with ductopenia  (HE  stain,  40× and  100× magniﬁcation  respec-
tively).  (C)  Perivenular  lymphocytic  inﬁltrate  (arrows)  (HE  stain,
1
a
dimilar  to  the  pancreatic  head,  where  the  puncture  was  made.
ain  pancreatic  duct  (MPD)  abnormalities.  An  endoscopic
ltrasound  (EUS)  showed  an  abnormal  pancreatic  head,
verall  hypoechoic,  heterogeneity  and  slightly  increased,
ith  no  MPD  visualization  (Fig.  2).  This  was  felt  suggestive
f  AIP  and  ﬁne  needle  aspiration  with  a  19  g  Trucut  nee-
le  (Cook)  at  the  pancreatic  neck  was  performed.  Histology
howed  extensive  pancreatic  ﬁbrosis,  marked  ductopenia,
iffuse  lymphocytic  inﬁltration  predominantly  periductal  as
ell  as  peri-venular  lymphocytic  inﬁltrates  (Fig.  3).  These
ndings  were  felt  to  support  the  diagnosis  of  AIP.
Additional  laboratory  evaluation  showed  increase  of  IgG4
212  mg/dl).  The  autoantibodies  studied  (ANA,  AMA,  Ac  Anti-
NA,  ASMA,  ANCA  e  ASCA)  and  the  rheumatoid  factor  were
ormal.
One  week  after  the  initial  diagnostic  workup,  the  patient
resented  with  blood-stained  diarrhea  and  abdominal  pain.
tool  culture,  stool  evaluation  for  ova  and  parasites  and
lostridium  difﬁcile  toxin  assay  were  negative.  Colonoscopy
howed  diffuse  continuous  superﬁcial  erosions  and  ulcera-
ions  throughout  the  entire  colon  and  rectum  with  loss  of
he  vascular  pattern.  Histology  supported  the  hypothesis
f  active  UC  diagnosis.
w
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The  clinical,  analytical,  imaging  and  histological  evalu-
tion  of  the  patient  therefore  allowed  for  establishing  the
iagnosis  of  AIP  associated  with  UC.
The  patient  was  started  on  prednisolone  40  mg  qd  for  2
eeks  combined  with  messalazine  3  gr  qd.  Rapid  remission
f  all  symptoms  was  noted  as  well  as  decreased  inﬂamma-
ory  parameters,  including  Ig  G4.
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Although  EUS  after  4  weeks  of  treatment  was  identical  to
the  initial  procedure;  the  biliary  stent  was  removed  and  no
cholestasis  recurrence  was  noted.
At  5-month  the  patient  is  in  complete  remission  with-
out  evidence  of  auto-immune  pancreatic  activity  (i.e.,
without  signs  or  symptoms  of  pancreatic  insufﬁciency  or
cholestasis).
Discussion
The  diagnosis  of  AIP  is  a  clinical  challenge,  not  only  due  to
its  rarity,  but  also  due  to  the  need  of  integrating  clinical,
laboratory,  imaging  and  histology  data  for  conﬁrmation.6,7
Because  of  that,  AIP  patients  are  frequently  submitted  to
multiple  exams,  and  some  of  which  are  invasive,  until  a
deﬁnitive  diagnosis  can  be  reached.  The  clinical  case  pre-
sented  here  is  an  example  of  that,  much  because  of  the
absence  of  characteristic  imaging  (such  as  the  lack  of  the
‘‘sausage-like’’  aspect  of  the  pancreas  on  the  CT  or  the
identiﬁcation  of  focal  pancreatic  lesions)  and  the  inability  to
obtain  a  pancreatography  by  ERCP,  which  in  case  of  AIP  typ-
ically  reveals  focal  segmental  or  diffuse  stenosis,  with  little
or  no  dilatation  of  the  amount  of  segments.6--9 Therefore,
EUS  proved  fundamental  in  this  case.  Although  no  imag-
ing  criteria  can  be  considered  pathognomonic,  morphology
on  EUS  raised  the  suspicion  which  lead  to  the  decision  of
obtaining  pancreatic  tissue,8,10,11 underscoring  the  fact  that
histological  evaluation  by  an  experienced  pathologist  could
be  considered  the  gold  standard.6,7,12--14
The  association  of  AIP  with  other  autoimmune  illnesses
can  be  identiﬁed  in  more  than  half  of  the  cases.11,13 They
can  precede  the  pancreatic  illness  diagnosis  or  present  later
during  the  natural  course  of  the  disease.9 Among  these,
the  association  with  IBD,  and  more  speciﬁcally  with  UC,
has  been  described,  being  the  most  common  in  an  Italian
series  (35%  of  analysed  cases).9,10,13 Overall,  however,  the
true  dimension  of  the  relationship  between  these  two  enti-
ties  is  still  not  totally  clear.  This  is  likely  due  to  the  fact
that  only  recently  AIP  has  been  considered  a  proper  noso-
logical  entity  with  well  deﬁned  diagnostic  criteria.  Indeed,
we  believe  that  previous  case  reports  referring  to  chronic
pancreatitis  with  indeterminate  aetiology  associated  to  UC
probably  were  cases  of  autoimmune  pancreatitis  based  on
current  diagnosis  criteria.15
In  fact,  the  observed  pancreatic  alterations  of  patients
with  UC  are  more  frequent  than  initially  expected.  Although
UC  patients  present  an  increase  incidence  of  gallbladder
lithiasis  and  are  administered  drugs  that  can  potentially
be  pancreato-toxic,  these  factors  alone  are  probably  not
enough  to  explain  the  great  incidence  of  pancreatic  alter-
ations  among  UC  patients.16 Some  studies  demonstrate
insufﬁcient  levels  of  pancreatic  exocrine  in  21--80%  of  IBD
patients  and  autopsy  studies  register  pancreatic  alterations,
macroscopic  or  microscopic,  in  14--53%  of  UC  patients.  Pan-
creatic  duct  changes,  such  as  irregularities  or  short-segment
stenosis  of  the  main  pancreatic  duct,  were  observed  in
8.4--10.8%  of  IBD  patients  independently  of  prior  history  of
pancreatitis  or  exocrine  insufﬁciency.4,17 It  seems  that  pre-
dominantly  asymptomatic  pancreatic  alterations  of  indolent
development  might  exist  in  these  patients,  albeit  the  fact
that  the  exact  aetiology  and  pathogenesis  are  still  poorly39
nderstood.  We  believe  that  a  large  spectrum  of  pancreatic
hanges  can  be  documented  in  IBD  patients,  from  symptom-
ree  cases  (likely  the  majority)  to  clinically  exuberant  forms
uch  as  the  case  of  our  patient.  The  aetiopathogenesis  could
e  related  to  an  abnormal  immunological  response  leading
o  pancreatic  inﬂammation  such  as  Ectors  et  al.  previously
uggested.18
The  association  between  AIP  and  UC  presents  a  clinical
hallenge  concerning  the  treatment  strategy.  UC  patients
eed  immunosuppressive  treatment  in  up  to  30%  of  cases.19
hiopurins  (azathioprine  and  6-mercaptopurine)  continue  to
e  the  most  widely  used.  However,  potential  pancreatic
dverse  effects  are  well  established,  raising  concerns  of  its
se  in  patients  with  AIP.  In  this  setting  other  therapies  (e.g.
ethotrexate  or  biological  therapy)  could  step-in  as  ﬁrst  line
ptions.20 There  are  some  authors  who  advise  against  the
se  of  thiopurins  in  AIP,  although  its  use  has  been  described
s  presenting  good  results  in  cases  of  relapse  of  AIP  with
 low  level  of  adverse  effects.21--23 Albeit  more  studies  are
eeded,  its  use  can  be  justiﬁed  to  avoid  long-term  treatment
ith  corticosteroids,  under  close  monitoring  for  pancreatic
oxicity.
In  respect  to  corticotherapy,  a  good  clinical  response  is
onsidered  by  some  groups  as  a  diagnostic  criterion  for  AIP.7
n  our  case,  a  clinical  and  analytical  improvement  was  seen,
ith  no  cholestasis  relapse  after  biliary  stent  removal.  Pan-
reatic  morphology  improvement  on  EUS  was  not  observed
fter  corticotherapy,  supporting  the  idea  of  an  irreversible
xtensive  ﬁbrotic  process.11
A  word  of  caution  is  in  order,  concerning  the  unevent-
ul  evolution  of  the  presented  case.  A  long-term  follow-up
trategy  is  mandatory,  namely  to  maintain  a  low  threshold
or  future  associated  autoimmune  illnesses.
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